If you typed iNGENū CRO into a search box, you are probably building a CRO shortlist. This article uses only what iNGENū CRO publishes (ingenucro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What iNGENū CRO publishes
iNGENū CRO is a Melbourne, physician-led biotech CRO led by CEO Dr Sud Agarwal. It sells fixed-milestone pricing, claims costs 80–90% below US CROs and 30–60% below other Australian CROs, and about four-week ethics. In September 2025 it was named CRO for Sapu Nano's Sapu003 human trials.
iNGENū CRO vs bioaccess®
| Dimension | iNGENū CRO | bioaccess® |
|---|---|---|
| Core focus | Lean Australian biotech CRO, drug-primary | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you are a lean US biotech looking for a low-cost Australian Phase 1, iNGENū is built for that.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including iNGENū CRO, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not iNGENū CRO features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the iNGENū CRO public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply